Rentschler Invests in New Stainless-Steel Bioreactors - - BioPharm International

ADVERTISEMENT

Rentschler Invests in New Stainless-Steel Bioreactors



Rentschler Biotechnologie GmbH, a CMO for the development and production of biopharmaceuticals, reported the investment of €24 million (approximately $32 million) to build a twin system with two 3000-L stainless-steel bioreactors mainly targeting market supply at the company’s site in Laupheim, Germany. The twin system should be operational in early 2017.

The twin system is designed for running two main bioreactors in parallel with one shared downstream processing unit, thus providing higher throughput while reducing incremental labor costs involved. It will be integrated into the existing 3000-L GMP line and will more than double the production capacities for cell culture-derived proteins. The twin system will allow Rentschler to run cell-culture processes in fed-batch mode with a high output in a single suite.

Source:Rentschler Biotechnologie GmbH

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Pfizer to Acquire Vaccines from Baxter
July 30, 2014
GSK Submits EU Regulatory Filing for Malaria Vaccine Candidate
July 29, 2014
Bristol-Myers Squibb and Ono Pharmaceutical Collaborate on Immunotherapies
July 28, 2014
FDA Accepts First Biosimilar Filing
July 24, 2014
Compounding Pharmacy Issues Recall, But Challenges FDA Decision
July 22, 2014
Author Guidelines

Click here